Armodafinil vs Vinpocetine

Mechanism

The isolated R-enantiomer of racemic modafinil, sharing the same primary mechanism — selective inhibition of the dopamine transporter (DAT) — but with distinct pharmacokinetics. The R-enantiomer has a terminal half-life of ~15 hours vs. ~4-5 hours for the S-enantiomer, resulting in 33-40% higher plasma AUC compared to equimolar racemic modafinil. This translates to more sustained wakefulness-promoting activity throughout the day. Same downstream activation of orexinergic, histaminergic, and noradrenergic pathways as modafinil.

Standard Dosing

75-150 mg once daily (for educational context only — prescription medication in most jurisdictions)

Timing

Early morning. 150 mg armodafinil provides comparable late-day wakefulness to 200 mg modafinil. Food delays Tmax by ~2-4 hours but does not affect total absorption. Half-life approximately 15-16.5 hours.

Cycle Duration

Same as modafinil; not typically cycled in clinical use.

Side Effects

• Headache
• Nausea
• Dizziness
• Insomnia (more pronounced than modafinil due to longer half-life)
• Anxiety
• Dry mouth
• Diarrhea
• Stevens-Johnson syndrome (very rare)

Contraindications

• Same as modafinil: mitral valve prolapse, left ventricular hypertrophy, severe hepatic impairment, severe anxiety/psychotic disorders, hypersensitivity, pregnancy

Best Stacking Partners

Mechanism

Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.

Standard Dosing

5-20 mg 2-3 times daily (15-60 mg/day total)

Timing

With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).

Cycle Duration

Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.

Side Effects

• Flushing
• GI distress
• Headache
• Dizziness
• Transient hypotension
• Sleep disturbance

Contraindications

• Severe hepatic impairment
• Pregnancy and lactation (FDA issued warning in 2019)
• Severe cardiac arrhythmias
• Recent hemorrhagic stroke

Best Stacking Partners